| Accession |
PRJCA009519 |
| Title |
Integration between MCL1 gene co-expression module and the RISS enables precise prognostication and prediction of response to proteasome inhibitor-based therapy in individual multiple myeloma |
| Relevance |
Medical |
| Data types |
Transcriptome or Gene expression
|
| Organisms |
Homo sapiens
|
| Description |
We recently identified a gene module of 87 genes co-expressed with MCL1 (MCL1-M), a critical regulator of plasma cell survival. MCL1-M captures both MM cell-intrinsically acting signals and the signals regulating the interaction between MM cells with bone marrow microenvironment. MM can be clustered into MCL1-M high and MCL1-M low subtypes. While the MCL1-M high MMs are enriched in a preplasmablast signature, the MCL1-M low MMs are enriched in B cell-specific genes. In multiple independent datasets, MCL1-M high MMs exhibited poorer prognosis compared to MCL1-M low MMs. Re-analysis of the phase III HOVON-65/GMMG-HD4 showed that only MCL1-M MMs, but not MCL1-M low MMs, benefited from bortezomib-based treatment. To translate the MCL1-M clustering scheme into a platform for individual diagnosis, we refined the classifier genes and developed a support vector machine-based algorithm. |
| Sample scope |
Multiisolate |
| Release date |
2024-03-26 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
|
|
Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple Myeloma
|
Research Square
|
10.21203/rs.3.rs-3995303/v1
|
2024
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Beijing Municipal Administration of Hospitals
|
|
ZYLX201606
|
Multiple Myeloma
|
|
|
| Submitter |
Yin
Wu (wudxuan@126.com)
|
| Organization |
Beijing Chaoyang Hospital, Capital Medical University |
| Submission date |
2022-05-10 |
